Tivic Health Systems Inc. (TIVC)
3.39
-0.02 (-0.59%)
At close: Mar 25, 2025, 3:53 PM
-0.59% (1D)
| Bid | 3.15 |
| Market Cap | 2.08M |
| Revenue (ttm) | 94.68K |
| Net Income (ttm) | -635.28K |
| EPS (ttm) | 91.29 |
| PE Ratio (ttm) | 0.04 |
| Forward PE | -0.01 |
| Analyst | n/a |
| Ask | 3.21 |
| Volume | 13,992 |
| Avg. Volume (20D) | 655,912 |
| Open | 3.41 |
| Previous Close | 3.41 |
| Day's Range | 3.21 - 3.41 |
| 52-Week Range | 2.85 - 31.45 |
| Beta | 1.91 |
About TIVC
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, includ...
Industry Medical - Devices
Sector Healthcare
IPO Date Nov 11, 2021
Employees 9
Stock Exchange NASDAQ
Ticker Symbol TIVC
Website https://www.tivichealth.com
3 weeks ago
-13.84%
Tivic Health Systems shares are trading lower afte...
Unlock content with
Pro Subscription
1 month ago
+197.5%
Tivic Health Systems shares are trading higher after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.
5 days ago · seekingalpha.com
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call TranscriptTivic Health Systems, Inc. (NASDAQ:TIVC ) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Of...
